

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of : Richard G. Olsen, *et al.*
Serial No. : 09/125,841
Filed: : January 19, 1999
For: : CELLULAR IMMUNOTHERAPY
TC/AU : 1644
Examiner : Ronald B. Schwadron, Ph.D.
Attorney Docket No. : CIR 2-001-3

HONORABLE COMMISSIONER FOR PATENTS
MAIL STOP APPEAL BRIEF-PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450


APPELLANTS' BRIEF ON APPEAL

Sir:

Responsive to a Communication mailed February 27, 2004, submitted herewith in triplicate is Appellant's Brief on Appeal as prescribed in 37 C.F.R. § 1.192. Reversal of the primary examiner's rejection of the appealed claims and their allowance is respectfully requested.

The requisite fee of \$165.00 as required in 37 C.F.R. § 1.17(c) is submitted herewith. Any additional payments that may be required should be charged to Deposit Account No. 13-4830.

Respectfully submitted,




Jerry K. Mueller, Jr.
Reg. No. 27,576
MUELLER AND SMITH, L.P.A.
MUELLER-SMITH BUILDING
7700 Rivers Edge Drive
Columbus, Ohio 43235-1355
tel.: 614-436-0600
fax: 614-436-0057
email: smueller@muellersmith.com

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service on August 27, 2004, as first class mail in an envelope addressed to:

Honorable Commissioner For Patents
MAIL STOP APPEAL BRIEF-PATENTS
P.O. Box 1450
Alexandria, VA 22313-1450


Jane Keeney

Real Party in Interest

The appealed application has been assigned by the Appellant, and currently is owned by the Cira Technologies, Inc., a Delaware Corporation.

Related Appeals and Interferences

There are no related appeals or interferences known to applicant, their legal representatives, or assignee that will directly affect or be directly affected by or have a bearing on the Board's decision in the pending appeal.

Status of Claims

Forty one (41) claims were submitted with the application as originally filed.

An Office Action was mailed on March 28, 2001 imposing a restriction requirement. Appellants elected claims 29-35 in a response mailed May 4, 2001.

An Office Action was mailed on December 10, 2001 rejecting claims 29-35 under 35 U.S.C. § 112 as being indefinite, and under 35 U.S.C. §103(a) as being obvious. In particular, Babbitt *et al.* (U.S. Patent No. 5,766,920) and separately Ochoa *et al.*, (U.S. Patent No. 5,443,983) were cited as the basis for the §103(a) rejections. responded with amendments to claims 29-35 in a response mailed June 4, 2002. also drew the Examiner's attention to an affidavit by Dr. Pierre Triozzi filed in a related Application No. 08/943,993, to which priority is claimed.

During prosecution there were several problems with the computer readable form of the sequence listing, including software errors, formatting errors, and damage to the submission in transit, despite ' extraordinary attempts to comply with the Sequence Rules. The Examiner issued a notice of abandonment for failure to comply with the Sequence Rules in a paper mailed June 24, 2003. complied with the Sequence rules and petitioned to withdraw the holding of abandonment in a response mailed August 25, 2003. ' Petition was granted and the holding of abandonment was withdrawn by a Notice mailed November 20, 2003.

An Office Action was mailed on February 27, 2004, rejecting all claims, and making the action final. The Examiner again rejected claims 29-35 under 35 U.S.C. § 112 as being indefinite, and under 35 U.S.C. §103(a) as being obvious. Babbitt *et al.* (U.S. Patent No. 5,766,920) and separately Ochoa *et al.*, (U.S. Patent No. 5,443,983) were cited as the basis for the §103(a) rejections. Because the Dr. Triozzi's affidavit that was part of the parent application's file history and with which the Examiner was familiar was not enclosed, neither the affidavit nor the arguments based on the affidavit were considered.

Appellants filed an Amendment and Response After Final by a facsimile on June 28, 2004, amending claims 29-35 in accordance with the Examiner's typographical suggestions. Appellants also submitted a copy of the affidavit of Dr. Triozzi, and requested reconsideration by the Examiner, or in the alternative, entry of the amendments and affidavit for purposes of appeal. Said submissions comply with 37 CFR 1.116, adopt the Examiner's suggestions and or require only a cursory review.

Appellants filed a notice of appeal by mail on June 28, 2004.

Thus, this appeal involves claims 29-35, directed to enriched T helper cell populations derived from patients infected with HIV.

Status of the Amendments

Appellants have requested entry of amendments to the claims submitted June 28, 2004.

Summary of the Invention

The invention is a novel approach to the adoptive cellular therapy of HIV infection that exploits the potentially effective cellular immune response that is initially generated in HIV-infected individuals. Application, p. 7, l. 30-p. 8, l.12. Cytokine-producing cells derived from lymph nodes excised from patients infected with HIV are subjected to mitogenic stimulation for their expansion. One aspect of the invention is a therapeutic agent for treating patients afflicted with HIV. Application p. 11, l.33-p. 12, l.24. The invention also is capable of inhibiting replication of HIV as measured by the viral load reductions exhibited by patients that receive the inventive therapeutic and capable of inducing an immunorestorative effect in HIV patients. Application, p. 12, l. 26-l. 34. Other aspects of the invention are described in the specification , including in the Examples.

Summary of the Rejection

Claims 29-35 stand rejected under 35 U.S.C. §103(a) as being obvious in light of Babbitt *et al.* (U.S. Patent No. 5,766,920) and separately Ochoa *et al.*, (U.S. Patent No. 5,443,983).

Claims 29-35 stand rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Appellant regards as the invention, namely because the claims recite "helper cells" which the Examiner considers unclear and prefers substitution of "T helper cells."

The oath and declaration was defective because it was not signed by inventor Olsen. The Examiner objected to the Appellants' claim of priority requesting removal of the phrase "based on" and requesting substitution of the phrase "is a 371 of."

Issues

1. Is the invention a nonobvious enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV in light of Babbitt *et al.* (U.S. Patent No. 5,766,920) and Ochoa *et al.*, (U.S. Patent No. 5,443,983)?
2. Do the claims particularly point out and distinctly claim the subject matter which Appellant regards as the invention under 35 U.S.C. §112, second paragraph?
3. Is the application in condition for allowance since the oath and declaration are in order and because the Application properly claims of priority?

Grouping of Claims

Claims 29-35 subject to the instant appeal are not being treated as a single grouping. The appealed claims do not stand or fall together for reasons given in conjunction with the arguments set forth below. Each appealed claim separately is believed to be patentable.

Argument

1. The invention is a nonobvious enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV.

Claims 29-35 stand rejected under 35 U.S.C. § 103(a) as being obvious over Babbitt *et al.* (U.S. Patent No. 5,766,920). Claims 29-35 also stand rejected under 35 U.S.C. § 103(a) as being unpatentable over Ochoa, *et al.* (U.S. Patent No. 5,443,983). Appellants respectfully traverse the rejections of the claims and grounds therefor.

Appellants teach use of excised lymph node tissue as a source of T helper cells because lymph nodes offer numerous advantages over other tissues as a cell source. Babbitt *et al.* teach use of peripheral blood as a preferred source of T-helper cells, and uses repetitive rounds of a multi-step procedure to co-stimulate the low numbers of T-helper cells present in peripheral blood. Lymph nodes on the other hand, are a complex tissue, enriched in antigen presenting cells, and particularly dendritic cells, both of which are at low concentrations in peripheral blood. Thus, Appellants submit that the invention taught by Babbitt *et al.* does not render obvious the expansion of activated T-helper cells derived from lymph nodes, because the two "tissues," though they share certain cell types, differ in their responses to cytokines and other stimuli. Appellants note that the amended claims do not claim use of peripheral blood lymphocytes as a source of mononuclear cells for the *in vitro* cell manipulation of the invention. Appellants actually teach away from using peripheral blood lymphocytes as a source of T-helper cells, because peripheral blood is ineffective to serve as a source of T-helper cells when used in the method taught in by the Appellants' invention.

The procedure disclosed by Appellants, contrary to that of Babbitt maintains the viability of antigen presenting cells present in lymph nodes. The present invention differs so substantially from that disclosed by Babbitt and offers such substantial improvements in ease of application and reliability that the ' invention is not obvious in light of Babbitt.

The novelty and nonobviousness of the Appellants' invention is emphasized by the affidavit of Dr. Pierre L. Triozzi. Dr. Triozzi, supervising a pilot study implementing an embodiment of the instant invention, reports the results of experiments comparing the cell expansion of CD4⁺ and CD8⁺ cells derived from peripheral blood and from excised lymph nodes. These results clearly show that CD4⁺ and CD8⁺ cells were expanded to a far lesser degree when the lymphocyte progenitors were derived from peripheral blood lymphocytes than when derived from lymph nodes. ¶ 7, 8 of Dr. Triozzi's December 18, 1997 affidavit. Next, Dr. Triozzi reports the results of cytokine production assays (MIP-1a and RANTES) from cells expanded from lymph node lymphocytes and from peripheral

blood lymphocytes. Again, the amount of cytokine produced from the cells expanded from lymph node lymphocytes was significantly greater than from cells expanded from peripheral blood. ¶¶ 9-11 of Dr. Triozzi's December 18, 1997 affidavit. Thus peripheral blood, as practiced by Babbitt is an inferior source for expansion of CD4⁺ and CD8⁺ cells, and for the production of cytokines by these cells.

The use of lymph node lymphocytes results in a much more effective treatment of HIV patients for both reduction of viral load and for restoration of immune function compared to peripheral blood lymphocytes. ¶ 12 of Dr. Triozzi's December 18, 1997 affidavit. These tests demonstrate that lymphocytes derived from such different sources as lymph nodes or peripheral blood do not possess equivalent generative potential. The source of lymphocytes surely impacts their use in adoptive cellular therapy. It is not surprising that prior workers in this field using peripheral blood lymphocytes for adoptive cellular therapy could not effectively treat HIV infection, whereas appellants show a therapeutic benefit.

It is without question that Dr. Triozzi is eminently qualified as an expert in this field. Dr. Triozzi supervised a pilot study, implementing an embodiment of the present invention disclosed and claimed in the application. The affidavit of Dr. Pierre L. Triozzi, was originally submitted in prosecution of the application Ser. No. 08/943,993, which is a continuation of Ser. No. 08/604,728, to which priority of the present application has been claimed. The Examiner, though he was aware of and had access to this affidavit, and though its contents were brought to his attention, declined to consider it during prosecution of the application. Appellants have already submitted a copy of Dr. Triozzi's affidavit, and again request its entry and consideration.

The Appellants' invention is nonobvious in light of Ochoa et al. because Ochoa similarly fails to recognize the advantage of using lymph nodes removed from a patient with HIV as a preferred tissue source. Appellants' invention teaches that excised lymph nodes from HIV infected patients are a preferred source for the expansion of T-helper cells of the invention. Ochoa is even less relevant than Babbitt, because Ochoa shows no preference for tissue source, so long as lymphocytes can be obtained. Ochoa does not even refer to lymph nodes. Therefore, the advantages of preferring lymph nodes as a tissue source under the Appellants' invention could not have been obvious to Ochoa.

Rather than generating a population of specific T helper cells, what Ochoa is attempting to accomplish is to simply generate "a large number of activated cells" while minimizing toxicity to the patient and avoiding repeated venipunctures. Ochoa, Col. 2, ll. 42-67. It is abundantly clear that Ochoa is not aware of the Appellant's invention, by

considering Example 4 of the Ochoa patent. Ochoa collected peripheral blood lymphocytes from the patient's twin brother in attempting to treat HIV. Ochoa, Col. 11, ll. 51-56. The appellants' invention is to use the lymph nodes of the infected patient as a source of cells for culture, rather than the peripheral blood of the uninfected brother. Clearly the advantages of the Appellants' invention are not obvious to Ochoa, because Ochoa's practice is contrary to the Appellants' invention.

Though the disclosures in Babbitt and Ochoa suggest in passing that lymph nodes could be used as a source of lymphocytes, lymph nodes are not a preferred source in the prior art. Indeed, there is no way to predict from the experimental results reported by Babbitt and Ochoa that lymph node lymphocytes would be a preferred, or even an enabling, source for basing an adoptive cellular therapeutic in the treatment of HIV patients. This is especially telling in view of the excellent data, including patient data, presented in the application. As Dr. Triozzi states, "If anything, it may be considered counter-intuitive to use a major reservoir of HIV, *i.e.*, lymph nodes, and the central target of HIV infection, *i.e.*, activated CD4⁺ cells, in the adoptive cellular therapy of HIV infection." ¶ 14 of Dr. Triozzi's December 18, 1997 affidavit. Thus Appellants' invention encompasses the nonobvious recognition that lymph nodes excised from HIV patients are the source of a cell population suitable for treating HIV caused disease.

Thus, the command to determine obviousness in accordance with the *Graham v. John Deere* tripartite test highlights the shortfalls of the references cited:

"To imbue one of ordinary skill in the art with knowledge of the invention in suit, when no prior art reference or references of record convey or suggest that knowledge, is to fall victim to the insidious effect of a hindsight syndrome wherein that which only the inventor taught is used against its teacher."

W.L. Gore & Assocs., Inc. v. Garlock, Inc., 721 F.2d 1540, 1553 (Fed. Cir. 1983).

The present invention demonstrates both surprising and unexpected efficacy by choosing infected lymph nodes from among the many potential sources of lymphocytes. Appellants' have presented clear, unrebutted evidence that no prior artisans could have recognized the advantages of the invention. Thus, neither the Babbitt citation nor the Ochoa citation renders obvious the present invention and Appellants have overcome these grounds for rejection.

2. The claims particularly point out and distinctly claim the subject matter which Appellant regards as the invention under 35 U.S.C. §112, second paragraph.

Claims 29-35 were rejected under 35 U.S.C. § 112, second paragraph, as being indefinite in the recitation of "helper cells." The Examiner stated in the rejection of record "the term 'helper cell' in itself has no art recognized meaning and is not defined in the specification. Therefore it is unclear what types of cells are encompassed by said term. A preferred substitution is 'T helper cells.'" ¶ 4 Office action dated February 27, 2004. Based on the application, it is abundantly clear that Appellants are referring to T-helper cells when using the shorthand "helper cells" phrase. Nevertheless, Appellants have previously submitted amendments to the claims substituting "T helper cells" for "helper cells" in claims 29-35, seeking to alleviate any concerns regarding indefiniteness with respect to this term. The meaning of "T-helper cells" and "helper cells" are supported in the specification, and recognized in the art. As Appellants have requested entry of the foregoing amendments to the claims, by adopting the Examiner's suggestions they have overcome the rejection. Appellants present these arguments in order to preserve the issue on appeal, but if the previously submitted amendments are entered, Appellants understand that this rejection would be moot.

3. The application in condition for allowance since the oath and declaration are in order and because the Application properly claims of priority.

Previously, a new declaration claiming priority to said applications was submitted with the signature of inventor Dr. Ridihalgh. A copy of the declaration with Dr. Olsen's signature is submitted concurrently. The specification was amended in a paper submitted previously to claim priority to parent applications 08/604,728 and PCT 97/02309, and adopting the Examiner's phrase "a 371 of." Thus so long as the amendments to the specification are entered, the Examiner's suggestions will have been adopted and Appellants request that these rejections be withdrawn on the grounds that they are moot.

Conclusion

Accordingly, Appellants respectfully urge the Board to overrule the rejection of the appealed claims and to permit the appealed application to pass to issue.

Respectfully submitted,



Jerry K. Mueller, Jr.
Reg. No. 27,576
MUELLER AND SMITH, L.P.A.
MUELLER-SMITH BUILDING
7700 Rivers Edge Drive
Columbus, Ohio 43235-1355
tel.: 614-436-0600
fax: 614-436-0057
email: smueller@muellersmith.com

APPENDIX

The Appealed Claims

Claims 1-28. (Cancelled)

29. (Previously Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion.
30. (Previously Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) and anti-CD3 monoclonal antibody.
31. (Previously Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) at about 600 IU/ml and anti-CD3 monoclonal antibody at between about 1 and 100 ng/ml.
32. (Previously Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) at about 600 IU/ml and anti-CD3 monoclonal antibody at between about 1 and 100 ng/ml, and wherein the amount of IL-2 is lowered to about 120 IU/ml after 7 days of expansion.
33. (Previously Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) at about 600 IU/ml and anti-CD3 monoclonal antibody at between about 1 and 100 ng/ml, wherein the amount of IL-2 is lowered to about 120 IU/ml after 7 days of

expansion, and wherein said expansion extends to at least about 10 days.

34. (Previously Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free macrophage media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) at about 600 IU/ml and anti-CD3 monoclonal antibody at between about 1 and 100 ng/ml.
35. (Previously Amended) An enriched T helper cell population expanded by subjecting cells derived from lymph nodes excised from patients infected with HIV to mitogenic stimulation in serum-free macrophage media for their expansion, wherein said mitogenic stimulation includes the presence of Interleukin-2 (IL-2) and anti-CD3 monoclonal antibody.

Claims 36-41. (Cancelled)



AF JFW

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/125,841	
	Filing Date	January 19, 1999	
	First Named Inventor	Richard G. Olsen	
	Art Unit	1644	
	Examiner Name	Ronald B. Schwadron, Ph.D.	
Total Number of Pages in This Submission	19	Attorney Docket Number	CIR 2-001-3


ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input checked="" type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Gerald L. Smith Mueller and Smith, P.A.
Signature	
Date	August 27, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Jane Keeney		
Signature		Date	August 27, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 165.00

Complete if Known

Application Number	09/125,841
Filing Date	January 19, 1999
First Named Inventor	Richard G. Olsen
Examiner Name	Ronald B. Schwadron, Ph.D.
Art Unit	1644
Attorney Docket No.	CIR 2-001-3

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☐ Deposit Account:

Deposit
Account
Number
Deposit
Account
Name

13-4830

Mueller and Smith, LPA

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	
SUBTOTAL (1)				(\$)	-----

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below		Fee Paid
Total Claims	<input type="text"/>	-20** =	<input type="text"/>	X	<input type="text"/>	<input type="text"/>
Independent Claims	<input type="text"/>	- 3** =	<input type="text"/>	X	<input type="text"/>	<input type="text"/>
Multiple Dependent					<input type="text"/>	<input type="text"/>

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) -----

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	165.00
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 165.00

SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Gerald L. Smith	Registration No. (Attorney/Agent)	22,009	Telephone	614-436-0600
Signature		Date	August 27, 2004		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.